Cardinal Health CEO Jason Hollar detailed the company's M&A strategy and growth drivers in an interview with Yahoo Finance. Hollar said the company has invested heavily to acquire platforms that accelerate its specialty pharma strategy, which is the fastest growing part of the pharma market, and expects to continue bolt-on acquisitions in the specialty space. He noted that branded pharmaceuticals represent 90% of the US pharmaceutical market by value but only 10% by volume, and that volume is a much greater indicator of Cardinal Health's profitability than revenue. Hollar added that drug pricing set by manufacturers does not directly impact the company's profitability, and that lower drug prices from policies like the IRA and MFN could drive additional volume, which is good for the business.
Cardinal Health IncCEO details M&A strategy and growth drivers, indicating active acquisition plans in specialty pharma.
